OncBioMune To Become Exclusive Distributor of Lipomed Drugs in Mexico
BATON ROUGE, LA--(August 10, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Submits Application to Commercialize Anti-Rabies Drug in Mexico
BATON ROUGE, LA--(August 3, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Acquires Propolis Product Line from German Partner
BATON ROUGE, LA--(July 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
Phase 2 Trial of ProscaVax for Early-Stage Prostate Cancer Nears Commencement
BATON ROUGE, LA--(July 13, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico
BATON ROUGE, LA--(June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
Enrollment to Begin in OncBioMune’s Trial of ProscaVax for Prostate Cancer in Mexico
BATON ROUGE, LA—(June 27, 2017) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico
BATON ROUGE, LA—(June 21, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Awarded Patent for ProscaVax in Japan
BATON ROUGE, LA--(June 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, [...]
OncBioMune Acquires Norepinefrine for Low Blood Pressure and Heart Failure in Mexico from Teva Pharmaceuticals Mexico
MEXICO CITY, MEXICO--(June 19, 2017) - OncBioMune México, S.A. De C.V., (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted [...]
OncBioMune, AqVida add additional drugs to distribution agreement (Paclitaxel and Oxaliplatin)
BATON ROUGE, LA--(June 15, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]
OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong
BATON ROUGE, LA--(June 07, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]
OncBioMune’s Andfrt(R) Shown in Clinical Trial to Improve Sperm Count and Mobility
BATON ROUGE, LA--(June 06, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies [...]
Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer
BATON ROUGE, LA—(June 01, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]
OncBioMune Reports Record Monthly Sales for Bekunis(R) in May
BATON ROUGE, LA--(May 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]
OncBioMune Receives Approval for Male Fertility Product in Mexico
BATON ROUGE, LA--(May 30, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]
OncBioMune CMO Begins Formulation Work on Tretinoin for Acute Promyelocytic Leukemia
BATON ROUGE, LA--(May 23, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
BATON ROUGE, LA--(May 9, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP)("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and [...]
OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer
BATON ROUGE, LA--(May 03, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer [...]
OncBioMune, AqVida Partner for Commercializing Cancer and Other Generic Drugs in Mexico
Companies Negotiating Joint Venture for Clinical Development of ProscaVax for Prostate Cancer in Europe BATON ROUGE, LA--(April 26, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or [...]
OncBioMune Licenses Tretinoin for the Treatment of Acute Promyelocytic Leukemia Throughout Mexico, Central and Latin America
BATON ROUGE, LA--(April 20, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer [...]